LATEST

• BUSINESS J&J's Drug-Device Combo Offers Weeks-Long Local Therapy for Bladder Cancer: Exec
  May 8, 2026

• REGULATORY MHLW Issues Q&A on Conditional Approval System
  May 1, 2026

• ORGANIZATION JPMA Launches New Legal Entity, Set for October Transition
  May 1, 2026

• BUSINESS Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
  May 1, 2026

• REGULATORY Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
  May 1, 2026

• BUSINESS Rohto Files CMV Corneal Endotheliitis Drug in Japan
  May 1, 2026

• BUSINESS Mochida Files in Japan for PAH Drug Tyvaso DPI
  May 1, 2026

• BUSINESS Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
  May 1, 2026

• BUSINESS 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
  May 1, 2026

• BUSINESS Jardiance Tops Four Promotion Channels in March: Intage
  May 1, 2026

• BUSINESS Sandoz Poaches Regeneron’s Yohei Ishii as Japan Chief
  April 30, 2026

• BUSINESS Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
  April 30, 2026

• BUSINESS FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
  April 30, 2026

• BUSINESS Otsuka’s IgA Drug Voyxact Sees Strong US Uptake: EVP
  April 30, 2026

• BUSINESS KM Biologics, India’s Serum Institute Partner on Japanese Encephalitis Vaccine
  April 30, 2026

• REGULATORY METI Clarifies Naphtha Comments, Reaffirms Medical Priority
  April 30, 2026

• REGULATORY Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
  April 30, 2026

• REGULATORY Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
  April 30, 2026

• REGULATORY Health Insurance Reform Bill Sails Through Lower House
  April 30, 2026

• BUSINESS Japan Drug Sales Top 11 Trillion Yen in FY2025, Keytruda Leads: Encise
  April 30, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »